3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma
15
Breast Neoplasms
13
Leukemia, Myeloid, Acute
11
Carcinoma, Non-Small-Cell Lung
11
Glioblastoma
10
Lymphoma, Non-Hodgkin
8
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma, Follicular
8
Brain Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Lymphoma, Mantle-Cell
7
Leukemia
7
Multiple Myeloma
6
Hodgkin Disease
6
Neoplasms
5
Myelodysplastic Syndromes
5
Lymphoma, T-Cell, Cutaneous
5
Lung Neoplasms
5
Gliosarcoma
5
Congenital Abnormalities
5
Breast Neoplasms, Male
5
Recurrence
4
Lymphoma, Large-Cell, Anaplastic
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Myelomonocytic, Acute
4
Leukemia, Monocytic, Acute
4
Leukemia, Megakaryoblastic, Acute
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Leukemia, Erythroblastic, Acute
4
Immunoblastic Lymphadenopathy
4
Interventions
blinatumomab
5
Rituximab
4
Cyclophosphamide
4
Brentuximab Vedotin
3
ponatinib
2
Vincristine
2
Prednisone
2
Etoposide
2
Doxorubicin
2
tetulomab tetraxetan lu-177
1
pembrolizumab
1
ibrutinib
1
ibritumomab tiuxetan
1
fludarabine
1
durvalumab
1
denileukin diftitox
1
cobomarsen
1
Vorinostat
1
Melphalan
1
Lutetium
1
Lenalidomide
1
Imatinib Mesylate
1
Ifosfamide
1
Everolimus
1
Cytarabine
1
Carmustine
1
Carboplatin
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphatic Diseases
×
Vorinostat
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts